JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 163 filers reported holding JUNO THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is 1.30 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $1,466,000 | +1.9% | 32,062 | 0.0% | 0.06% | -1.8% |
| Q3 2017 | $1,438,000 | +50.1% | 32,062 | 0.0% | 0.06% | +51.4% |
| Q2 2017 | $958,000 | +43.6% | 32,062 | +6.7% | 0.04% | +42.3% |
| Q1 2017 | $667,000 | +60.3% | 30,062 | +36.3% | 0.03% | +52.9% |
| Q4 2016 | $416,000 | -37.2% | 22,062 | 0.0% | 0.02% | -37.0% |
| Q3 2016 | $662,000 | -9.1% | 22,062 | +16.5% | 0.03% | -15.6% |
| Q2 2016 | $728,000 | +1.0% | 18,937 | 0.0% | 0.03% | 0.0% |
| Q1 2016 | $721,000 | – | 18,937 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 1,864,174 | $85,211,000 | 94.86% |
| Crestline Management, LP | 7,631,631 | $348,841,000 | 35.74% |
| Omega Fund Management, LLC | 753,564 | $34,445,000 | 24.90% |
| DDD Partners, LLC | 191,458 | $8,752,000 | 3.40% |
| SIB LLC | 100,000 | $4,571,000 | 3.28% |
| PECONIC PARTNERS LLC | 433,587 | $19,819,000 | 2.85% |
| Cormorant Asset Management, LP | 550,000 | $25,141,000 | 2.63% |
| ARK Investment Management | 682,495 | $31,197,000 | 2.48% |
| BB BIOTECH AG | 1,925,000 | $87,992,000 | 2.48% |
| Clarius Group, LLC | 120,988 | $5,530,000 | 2.47% |